Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Livmoniplimab by AbbVie for Solid Tumor: Likelihood of Approval
Livmoniplimab is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Livmoniplimab by AbbVie for Ovarian Cancer: Likelihood of Approval
Livmoniplimab is under clinical development by AbbVie and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Livmoniplimab by AbbVie for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Livmoniplimab is under clinical development by AbbVie and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
Livmoniplimab by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Livmoniplimab is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of AbbVie's Livmoniplimab?
Livmoniplimab is a monoclonal antibody commercialized by AbbVie, with a leading Phase III program in Metastatic Hepatocellular Carcinoma (HCC). According...